-
Study Identifies Key Barriers and Promoters in Translating Hereditary Angioedema Research to Clinical Care
14 Oct 2025 16:41 GMT
… clinical care for patients with hereditary angioedema (HAE). The study was … Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol … with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis. Allergy …
-
Innovations in Hereditary Angioedema Treatment: Present & Future
11 Oct 2025 13:45 GMT
… the Management of Hereditary Angioedema: Exploring Current and Future Therapies
Hereditary Angioedema (HAE) is … the debilitating impacts of hereditary angioedema.
Subject of Research: Hereditary Angioedema Treatments and Therapies …
-
Pipeline Report 2025: Late-stage programs set to reshape treatment
16 Oct 2025 16:20 GMT
… and on-demand treatment of hereditary angioedema (HAE). Visterra/CSL … Drug: Deucrictibant
Company: Pharvaris
Indication: Hereditary angioedema (HAE)
Stage: Phase III
… become the first treatment for hereditary angioedema (HAE) to demonstrate efficacy …
-
BioCryst to Acquire Astria Therapeutics in $700M Deal to Strengthen HAE Pipeline
16 Oct 2025 12:43 GMT
… its portfolio of treatments for hereditary angioedema (HAE).
The deal, unanimously approved …
-
BioCryst inks $700M Astria buyout to challenge Takeda for rare disease market
16 Oct 2025 03:02 GMT
… commercial infrastructure for its oral hereditary angioedema (HAE) drug Orladeyo and eager …
-
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M
16 Oct 2025 02:23 GMT
… to deepen its expertise in hereditary angioedema, BioCryst is scooping up Massachusetts … a key disease pathway in hereditary angioedema (HAE), a genetic disorder characterized …
-
BioCryst goes ‘all in’ on rare swelling disease with Astria deal
15 Oct 2025 15:39 GMT
… deal centered around an experimental hereditary angioedema medicine in late-stage testing … the swelling episodes associated with hereditary angioedema. Phase 3 data are expected … in 2027.
Dive Insight:
Hereditary angioedema, while rare, has become a …
-
<![CDATA[Roundup: Biopharmaceutical Industry Activity Accelerates with Focus on Rare Diseases and Novel Therapies]]>
15 Oct 2025 17:07 GMT
… inhibitor of plasma kallikrein for hereditary angioedema (HAE) prophylaxis.1 Navenibart’s …
-
BioCryst to buy Astria Therapeutics for $700m in enterprise value
15 Oct 2025 16:53 GMT
… kallikrein for the prophylaxis of hereditary angioedema (HAE).
Navenibart is in Phase …
-
STAT+: J&J reportedly in talks to buy Protagonist
15 Oct 2025 13:05 GMT
… -stage clinical development to treat hereditary angioedema, or HAE, a serious tissue …
About
© 1995-2025